WHWK · Whitehawk Therapeutics, Inc.
$3.83
-0.16 (-4.01%)
At close · Jul 23
Market Cap
$189.40M
Shares
49.45M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.15M
-72.5%
FY2025
Net Income
-$20.6M
+67.7%
FY2025
Gross Margin
89.36%
+1pp
FY2025
Operating Margin
-1601.12%
-1341.5pp
FY2025
Diluted EPS
-$0.33
+86%
FY2025
Operating Cash Flow
-$97.43M
-63.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $7.15M | $25.98M | $24.35M | $15.22M | $1.12M | $15M | $20.16M | $20.16M | — | — | — | — | — | — | — | |
| $0 | $760K | $3.02M | $2.81M | $1.34M | — | — | — | — | — | — | — | — | — | — | — | |
| $0 | $6.39M | $22.96M | $21.55M | $13.88M | — | — | — | — | — | — | — | — | — | — | — | |
| — | 89.36% | 88.36% | 88.47% | 91.23% | — | — | — | — | — | — | — | — | — | — | — | |
| $99.41M | $90.96M | $51.03M | $48.93M | $32.66M | $19.67M | $12.59M | $12.82M | $17.85M | $12.15M | — | — | — | — | — | — | |
| — | — | — | — | — | $18.51M | $8.76M | $9.76M | $13.49M | $9.24M | $29.49K | $23.01K | $165.4K | $141.42K | $118.6K | $96.21K | |
| $23.3M | $29.82M | $36.75M | $44.55M | $40.18M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $0 | $87K | $95K | — | — | — | — | — | — | — | — | — | — | |
| — | $79K | $193K | $169K | $159K | $105K | — | — | — | — | — | — | — | — | — | — | |
| $0 | $0 | $2.64M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $112.34M | $21.36M | $24.44M | $31.34M | $21.39M | — | — | — | — | — | — | |
| $122.7M | $121.55M | $93.44M | $96.29M | $77.9M | — | — | — | — | — | — | — | — | — | — | — | |
| -$122.7M | -$114.4M | -$67.46M | -$71.93M | -$62.68M | -$111.22M | -$6.36M | -$24.44M | -$11.18M | -$21.39M | -$29.49K | -$23.01K | -$181.04K | -$157.07K | -$134.24K | -$111.85K | |
| — | -1601.12% | -259.62% | -295.36% | -411.94% | -9930.09% | -42.38% | -121.27% | -55.47% | — | — | — | — | — | — | — | |
| — | -$114.32M | -$67.27M | -$71.76M | -$62.52M | -$111.11M | — | — | — | — | — | — | — | — | — | — | |
| — | $0 | $154K | $231K | $230K | $665K | — | — | — | — | $9942 | $8434 | $24K | $17.18K | $11.3K | $6324 | |
| $6.77M | $6.23M | $3.93M | $6.4M | $2.4M | $13K | — | — | — | — | — | — | — | — | — | — | |
| $6.9M | $93.8M | $3.77M | $6.17M | $2.17M | $1.13M | $2.04M | $1.17M | $784.61K | -$12.06K | — | — | — | — | — | — | |
| — | -$20.6M | -$63.69M | -$65.77M | -$60.51M | -$110.09M | — | — | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $2000 | — | — | — | — | — | — | — | — | — | — | |
| -$115.81M | -$20.6M | -$63.69M | -$65.77M | -$60.51M | -$110.09M | -$4.32M | -$23.27M | -$10.4M | -$21.4M | -$39.43K | -$31.44K | -$205.04K | -$174.24K | -$145.54K | -$118.18K | |
| — | -288.26% | -245.13% | -270.04% | -397.69% | -9829.46% | -28.77% | -115.44% | -51.58% | — | — | — | — | — | — | — | |
| — | — | — | — | -$60.51M | — | -$4.32M | -$23.27M | -$10.4M | -$22.34M | — | — | — | — | — | — | |
| -$115.82M | -$20.49M | -$63.7M | -$65.62M | -$60.63M | -$110.74M | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$0.33 | -$2.36 | -$2.44 | -$2.69 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.33 | -$2.36 | -$2.44 | -$2.69 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 61.89M | 27.03M | 26.92M | 22.51M | 8.92M | 2.84M | 2.71M | 2.26M | 1.44M | 333.33K | 333.33K | 329.75K | 329.16K | 328.35K | — |
| shares | — | 61.89M | 27.03M | 26.92M | 22.51M | 8.92M | 2.84M | 2.71M | 2.26M | 1.44M | 333.33K | 333.33K | 329.75K | 329.16K | 328.35K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2022: $4.41M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.58×
EV/EBIT
—
Biotechnology median 26.67×
P/E (TTM)
—
Biotechnology median 7.06×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $7,145,000 | $25,983,000 | — |
| Reportable Segment | — | — | $24,354,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $7,145,000 | $25,983,000 | $24,354,000 | $15,216,000 | $0 | — |
| Grant | — | — | — | — | $120,000 | $580,000 |
| License | — | — | — | — | $1,000,000 | $14,000,000 |